414 filings
8-K
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
10-Q
2024 Q1
COCP
Cocrystal Pharma Inc
Quarterly report
13 May 24
8:00am
DEF 14A
COCP
Cocrystal Pharma Inc
Definitive proxy
7 May 24
4:30pm
8-K
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
PRE 14A
COCP
Cocrystal Pharma Inc
Preliminary proxy
26 Apr 24
5:12pm
8-K
tpztvj
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
ypjvbmjsy3r nw8m3fx
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
bynlg0g8qr
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
gvi2973o6d4t
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
k9bme
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
yxl5tk02s0 o1g3
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
bf9ckurl5h
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
1o9nb1 c08jhy7b
4 Dec 23
Regulation FD Disclosure
8:00am
8-K
e8cl2 io9
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
bpmwx2
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
z5u2j yr19sdc2bi73wb
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
mdh7jjs7klmtscex2nzq
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm